Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00667121 · ClinicalTrials.gov registry record
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 88
- Enrollment target
NCT00667121: Completed study, sponsored by Mayo Clinic.
NCT00667121 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 88 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00667121 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 88 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of blood in the laboratory from patients receiving tamoxifen may help doctors learn more about the effects of other drugs on the level of tamoxifen in the blood. PURPOSE: This clinical trial is studying levels of tamoxifen in the blood of women with breast cancer and in women at high risk of breast cancer who are receiving tamoxifen together with venlafaxine, citalopram, escitalopram, gabapentin, or sertraline.
Interventions
- DRUG tamoxifen citrate
- DRUG gabapentin
- DRUG sertraline hydrochloride
- DRUG citalopram hydrobromide
- DRUG escitalopram oxalate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2011-03-16 |
| Est. Completion | 2014-05-27 |
What the finished NCT00667121 record still lists
NCT00667121 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 88 participants, a relatively small participant target.
The record links to 0 conditions, and to 5 interventions - of which tamoxifen citrate is the first listed.
NCT00667121 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00667121 about?
NCT00667121 is a clinical study titled "Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline". RATIONALE: Studying samples of blood in the laboratory from patients receiving tamoxifen may help doctors learn more about the effects of other drugs on the level of tamoxifen in the blood. PURPOSE: This clinical trial is studying levels of tamoxifen in the blood of women with breast cancer and in ...
What is the current status of trial NCT00667121?
This trial is currently completed. The enrollment target is 88 participants. The study started on 2011-03-16. Estimated completion is 2014-05-27.
What interventions are being tested in trial NCT00667121?
The interventions under investigation include: tamoxifen citrate (DRUG), gabapentin (DRUG), sertraline hydrochloride (DRUG), citalopram hydrobromide (DRUG), escitalopram oxalate (DRUG).
Who is sponsoring clinical trial NCT00667121?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI